Everest Medicines announced positive results in preliminary analysis of Phase 1b/2a clinical trial of EVER001, its next-generation, globally owned covalent reversible Bruton’s Tyrosine Kinase (BTK) ...

Roche presented new data at the ASH 2024 meeting highlighting the effectiveness of its bispecific antibodies, Columvi and Lunsumio, in treating l ...